| 764228 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
548 Phase 2 study of FLX475 in combination with ipilimumab in advanced melanoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.548 |
Goyal Rakesh, Nasrah Nicole, Johnson Dan, Ho William |
| 764227 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
207 Enhanced antigen capture, antigen-presenting cell (APC)-like function, and cytotoxic responses with chimeric engulfment receptor (CER) T cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.207 |
Corey Daniel, Thomas Sunil, Cieniewicz Brandon, Nguyen Linh, Clever Jared, Brysting Josephine, Vezan Remus, Rossi John, Diem Kurt, Jin Lei, Corey Lawrence |
| 764226 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
206 The development of ‘chimeric CD3e fusion protein’ and ‘anti-CD3-based bispecific T cell activating element’ engineered T (CAB-T) cells for the treatment of solid malignancies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.206 |
Tsun Andy, Li Zhiyuan, Zhang Zhenqing, Huang Weifeng, Peng Shaogang, Chai Jitian |
| 764225 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
205 AgenT-797, a native allogeneic ‘off-the-shelf’ iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models |
2021-11-01 |
10.1136/jitc-2021-sitc2021.205 |
Yigit Burcu, Moskowitz Darrian, Michelet Xavier, Tanne Antoine, Dijk Marc Van |
| 764224 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
203 A membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.203 |
Ding Jian, Webb Lindsay, Patterson Troy, Fleury Michelle, Zieba Adam, Horton Holly, Hofmeister Robert, Gutierrez Dario, Tighe Robert |
| 764223 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
200 TGFβ-armoring boosts potency and persistence of engineered TCR T cells, unlocking superior efficacy against HPV-positive solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.200 |
Turner Gail, Diaz Gabriela, Costa Andreia, Oh Yeonjoo, Huang Jianguo, Bailey Jenna, Imus Cyr De, Busch Stephanie, Foy Teresa, Sivakumar Pallavur, Salmon Ruth, Cleyrat Cédric |
| 764222 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
199 Potent T cell costimulation mediated by a novel costimulatory antigen receptor (CoStAR) with dual CD28/CD40 signaling domains to improve adoptive cell therapies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.199 |
Sykorova Martina, Bao Leyuan, Chauvin-Fleurence Cynthia, Kalaitsidou Milena, Brocq Michelle Le, Hawkins Robert, Kueberuwa Gray, Bridgeman John, Alvarez-Rodríguez Rubén |
| 764221 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
195 Stimulation of tumor infiltrating B-cells improves ex-vivo TIL expansion for melanoma immunotherapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.195 |
Rossetti Renata, Tordesillas Leticia, Beatty Matthew, Chen Yian Ann, Du Dongliang, Sarnaik Amod, Pilon-Thomas Shari, Abate-Daga Daniel |
| 764220 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
193 The Achilles VELOSTM Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.193 |
Kotsiou Eleni, Robinson Joe, Rogers Amber, Melandri Daisy, Baker Amy, Aragon Anabel Ramirez, Nawaz Sidra, Epstein Michael, Patel Shreenal, Mootien Jennine, Craig Andrew, Kaur-Lally Satwinder, Patel Hinal, Schmitt Andreas, Islam Farah, Jamal-Hanjani Mariam, Lawrence David, Foster Martin, Turajlic Samra, Quezada Sergio, Newton Katy |
| 764219 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
192 Pooled T cell receptor screening (POTS) provides unbiased, high-throughput method for TCR discovery |
2021-11-01 |
10.1136/jitc-2021-sitc2021.192 |
Reid Jack, Zhang Shihong, Munkhbat Ariunaa, Ecsedi Matyas, McAfee Megan, Chapuis Aude |
